Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGON
SELLCG Oncology, Inc. · Healthcare · United States · $6.1B · Avg Vol: $81M/d
COMPANY DESCRIPTION
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer. Its lead candidate, cretostimogene grenadenorev, is designed to selectively replicate in and destroy cancer cells while stimulating an anti-tumor immune response. The company's potential competitive moat lies in its innovative oncolytic virus platform targeting specific cancer types, positioning it as a specialized player in the immuno-oncology space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 0.2M | 1.1M | 4.0M | 176.6% | 5.1M | 11.8M | 88.3M | 367.4% |
| EPS | -11.71 | -15.65 | -1.41 | -2.08 | — | -2.28 | -2.67 | -2.75 | — |
| Shares | 63.5M | 63.5M | 76.2M | 80.7M | +27.1% | 88.2M | — | — | — |
| Debt | 15.9M | 0.5M | 0.2M | 7.0M | -23.9% | 7.6M | — | — | — |
| Equity | 125.2M | 184.8M | 733.4M | 752.6M | 81.8% | — | — | — | — |
| Op CF | -29.8M | -45.7M | -78.7M | -132.3M | — | -160.0M | — | — | — |
| Inv CF | -55.4M | -121.2M | -300.8M | -245.8M | — | — | — | — | — |
| Fin CF | 119.7M | 87.0M | 628.3M | 153.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGON are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGON | CG Oncology, Inc.(you) | $6.1B | 24 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 25 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 30 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%